Fluorescent detection of calcium mobilization has been used successfully to identify modulators of G-protein-coupled receptors (GPCRs); however, inherent issues with fluorescence may limit its potential for high-throughput screening miniaturization. The data presented here demonstrate that the calcium-sensitive photoprotein aequorin (AequoScreen™), when compared with FLUO-4 in the same cellular background, allows for miniaturization of functional kinetic calcium flux assays, in which the rank order of potency and efficacy was maintained for a series of diverse small-molecule modulators. Smallvolume (<10 μL) 384-and 1536-well aequorin assays were implemented by integration of acoustic dispensing (Echo 550™) and kinetic flash luminometry (CyBi Lumax™). The enhanced high signal-to-background ratios observed relative to fluorescence were readily manipulated by altering per-well cell densities and yielded acceptable screening statistics in miniaturized format for both agonist and antagonist screening scenarios. In addition, the authors demonstrate the feasibility of using agonist concentrations less than EC 50 in a miniaturized antagonist assay. These features, coupled with improved sample handling, should enhance sensitivity and provide the benefits of miniaturization including cost reduction and throughput gains. (Journal of Biomolecular Screening 2008:486-493) 
INTRODUCTION
S OME ESTIMATES INDICATE that the pharmaceutical industry must triple the number of new entities screened each year to meet the increasing demand for new drug candidates. 1 In addition, it must keep up with the rapid discovery of new targets aided by advances in genomics. [2] [3] [4] All of this must be done while dealing with pressure from the public and competing companies to decrease the costs of drug discovery. [2] [3] [4] The solutions for industrial high-throughput screening (HTS) laboratories have been to miniaturize screening volumes to realize proportional savings in reagent costs and to test compounds in high-density formats (i.e., 1536-well microplates) to reduce the amount of time needed to complete large screening campaigns while maintaining scientific rigor and assay quality. 2 Miniaturized cell-based functional assays have become increasingly important in HTS. 1 Advances in fluorescence detection technologies, such as the Fluorometric Imaging Plate Reader (FLIPR™; MDS Sciex, Sunnyvale, CA), have made intracellular calcium mobilization assays mediated by G-proteincoupled receptors (GPCRs) amenable to HTS. [3] [4] [5] Although HTS groups have been successful in identifying modulators of GPCRs using fluorescent detection methods, inherent issues with fluorescence make reducing assay volumes difficult, most notably autofluorescence and a marginal signal-to-background ratio (S:B).
Fluorescent calcium mobilization assays detect fluorescence in the microplate wells, whether it is from dye bound to calcium released upon receptor activation or bound to free intracellular calcium from other sources. Combined with the autofluorescence of microplates, reagents, compounds, and cells, the result is significant background fluorescence that must be overcome in fluorescent assays by densely seeding the microplate with cells (20,000-30,000 cells/well). 5 Although increasing cell density multiplies the available number of receptors to activate, it also proportionately elevates background fluorescence (autofluorescence of cells). Fluorescent dyes must be loaded into cells at high concentrations (20-200 μM) , resulting in maximal S:B ratios of approximately 4:1. 6 The variation, or "noise," in the fluorescent signal as well as background is increased when dye is sequestered into organelles and/or leaked from the membrane to bind extracellular calcium. 7, 8 As assay volumes are reduced and the corresponding absolute signal generated (e.g., relative light units) is diminished, the susceptibility to subtle variations such as cell heterogeneity and assay mixing is likely to increase and thereby result in less robust data. Aequorin, a luminescent biosensor, offers an alternative method for measuring changes in intracellular calcium.
Aequorin is the covalent reconstitution of apoaequorin, a 21-kDa bioluminescent photoprotein, and coelenterazine, its hydrophobic prosthetic group. [8] [9] [10] [11] Aequorin, isolated from the jellyfish, Aequorea victoria, has been used as a calcium indicator for the past 30 y. [6] [7] [8] When aequorin binds calcium at 3 high-affinity sites in the presence of oxygen, blue light is emitted in a dosedependent manner. [8] [9] [10] [11] Early in its development as a biosensor, aequorin had to be microinjected, which limited the use of this indicator to large, robust cells. [8] [9] [10] [11] However, advances in genetics and molecular biology have allowed scientists to clone aequorin DNA and heterologously express it in cell lines instead of loading by microinjection. [8] [9] [10] [11] Incorporating post-translational protein-targeting sequences into the cDNA encoding aequorin, mitochondrial-targeted aequorin expression has been enabled to increase the photon production of aequorin assays. 12 This helped overcome the limitation of lower cytosolic calcium concentrations and the lower calcium binding affinity of aequorin when compared to fluorescent dyes (10 μM for aequorin v. 400 nM for FLUO-4). Upon agonist stimulation of a Gα q -coupled receptor, Gα q activates phospholipase Cβ, which cleaves phosphatidylinositol bisphosphate into inositol 1,4,5-trisphosphate (IP 3 ) and diacyglycerol. 12,13 IP 3 binds ryanodine receptors on the surface of the endoplasmic reticulum, resulting in the concomitant release of calcium into the cytoplasm. 12, 13 Mitochondrial uptake of released calcium exposes mitochondrially targeted aequorin to higher calcium concentrations than cytosolic aequorin, resulting in an increased luminescent signal. 12 Another aequorin signal enhancement has been the use of synthetic coelenterazine h, which gives rise to greater luminescence intensity when compared with native coelenterazine. 10 These molecular modifications of the aequorin system have not been shown to affect the kinetics or pharmacology of the assay, as mitochondrial and cytosolically expressed aequorin are virtually the same, and calcium determinations using cytosolic aequorin closely match those of Fura-2. 8 The higher signal output and the negligible background of this system contribute to large (>4-fold) S:B ratios when compared with traditional fluorescence assays (2-to 4-fold). This allows for a large dynamic range of [Ca 2+ ] detection (0.3-10 μM) and facilitates screening for receptor antagonists, which must block an agonist-induced signal. 7, 8 The aequorin format, if amenable to small-volume miniaturization, could yield significant advantages over the conventional fluorescence-based platform. Although the feasibility of miniaturization for fluorescent-based detection of agonist and antagonists of GPCR targets has been reported, the robustness presented (agonist: Z′ 0.56 ± 0.21; antagonist: Z′ 0.53 ± 0.22) appears marginal with respect to Z′ of 0.5, a value widely used for determining statistical acceptability. [14] [15] [16] [17] [18] [19] [20] Several reports have described the utility of using aequorin-based detection of calcium mobilization for GPCR HTS and have made comparisons with fluorescence in relatively large-volume formats (i.e., 96-and 384-well assays). Given the significant difference between S:B ratios that exist between the fluorescence and luminescence methods 15, 16 and assuming that the variability of signal generated in response to GPCR activation is comparable, it is predicted that the aequorin method may yield a more robust assay in a miniaturized setting. Thus, it would be worthwhile to investigate the feasibility of miniaturizing the aequorin assay in small-volume 384-well and 1536-well microplate formats for use in GPCR HTS.
In 1999, Schaeffer and others 17 used cytosolic aequorin in a 96well microplate format to pharmacologically characterize 5hydroxytryptamine 2a and 5-hydroxytryptamine 2c (5-HT 2a and 5-HT 2c ) receptors in HEK293 cells. For the following experiments, an AequoScreen™ Chinese Hamster Ovary-K1 (CHO-K1) cell line stably expressing mitochondrially targeted apoaequorin and human 5-hydroxytryptamine 2b (5-HT 2b ) receptor was loaned for evaluation by Perkin Elmer Euroscreen (Brussels, Belgium). 5-HT 2b is a Gα qcoupled serotonin receptor associated with valvular heart disease 18 and was chosen for this study because of the abundance of known full and partial agonists and antagonists with varying potencies. Eight 5-HT 2b ligands were used to compare the pharmacology of the receptor in fluorescence and luminescent aequorin assays in 384-well, small-volume 384-well, and 1536-well formats.
MATERIALS AND METHODS

Cell culture
The AequoScreen™ CHO-K1 cell line, heterologously expressing 5-HT 2b receptor and apoaequorin, was cultured in T-175 flasks at a density of 75% to 90% confluency. The complete media (F-12 Hams nutrient mixture, 10% fetal bovine serum, 400 μg/mL G418, and 250 μg/mL zeocin) was discarded, and cells were washed with 15 mL Dulbecco's phosphate-buffered saline (DPBS; Invitrogen, Madison, WI). The DPBS were decanted, and 10 mL 1× 0.05% Trypsin-EDTA (Invitrogen) was added to the flasks before incubating at 37 °C for 10 min. After incubation, the cell suspension was collected in complete media and pelleted at 1000g for 5 min. The supernatant was decanted and the pellet resuspended in 10 mL Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) with 10,000 U/mL penicillin-streptomycin (Invitrogen) diluted 1:100. The cell suspension was counted on the Guava Personal Cell Analysis System (Guava Technologies, Hayward, CA) and diluted with DMEM (with penicillin-streptomycin) to a density of 1 × 10 6 cells/mL for fluorescent experiments and 5 × 10 6 cells/mL for aequorin experiments. Cells for aequorin experiments were prepared as previously described. 10 Briefly, one 250-μg aliquot of coelenterazine h (Invitrogen) was dissolved with methanol to a concentration of 500 μM. The coelenterazine solution was added to the cell suspension for aequorin assays to a final concentration of 5 μM. The suspension was gently rocked on an orbital shaker at room temperature during loading for 4 h prior to using the cells in experiments.
Cells for fluorescence experiments were prepared as previously described. 18 Briefly, cells were plated at a density of 20,000 cells/40 μL/well, lidded, and incubated at 37 °C overnight in black, sterile, clear-bottom, tissue culture-treated, standard-volume, 384well polystyrene microplates (Becton Dickinson, Franklin Lakes, NJ). The next day, growth media were removed from the cell plates 1 h before testing and replaced with a 5-μM final concentration of FLUO-4 (Teflabs, Austin, TX) dissolved in Hank's Balanced Salt Solution (BSS) supplemented with 1 mM final concentration HEPES and 2 mM final concentration probenecid (Sigma Aldrich, St. Louis, MO).
Assays
Compound plate preparation. The agonists and antagonists used in the following assays were dissolved in DMSO at 10 mM. The compounds were then serially diluted in 20 half-log increments in 384-well polypropylene microplates on the Genesis liquid handler (Tecan USA, Research Triangle Park, NC). For aequous compound dilution assays, a 1-μL daughter plate was created using a 384-well compound transfer station and diluted 100fold (2×) with Hanks BSS/10 mM HEPES. Compounds for acoustic dispensing were dissolved in DMSO at 10 mM and serially diluted in half-log increments in a Labcyte-certified flat 384well polypropylene microplate. Using the Echo 550™ (Labcyte, Sunnyvale, CA), compounds were ejected in 20-nL amounts from the plate directly into an assay plate.
Agonist assays. Assays were conducted using the same 5-HT 2b aequorin cell line in both fluorescence and aequorin luminescence modes. For direct comparison between the FLUO-4 and aequorin assays, experiments were conducted in standard-volume (up to 120 μL) 384-well microplates on the Hamamatsu FDSS 6000™ (Hamamatsu Photonics K.K., Hamamatsu City, Japan). For agonist assays, 20 μL of cells were dispensed into all wells of a microplate containing 20 μL/well of a 2× 20-point serial dilution of the following 5-HT 2b agonists from Sigma Aldrich: 5hydroxytryptamine hydrochloride (5-HT), R-(+)-SCH-23390 HCl (SCH-23390), BW-723C86, and (+/-)-8-hydroxy-2-(Di-N-Propylamino Tetralin) (8-OH DPAT). Measurements of integrated area under the curve, or integrated area, commenced immediately after the cell dispensation and continued for 20 s using FDSS™ software (Hamamatsu Photonics K.K.).
Antagonist assays. For antagonist assays, 20 μL of cells were dispensed into all wells of a microplate containing 20 μL/well of a 2× 20-point serial dilution for the following 5-HT 2b antagonists from Sigma Aldrich: methiothepin mesylate, LY-53,857 maleate, SB 204741, and mianserin hydrochloride. After a 15min room-temperature incubation, 20 μL of a 3× EC 50 concentration (previously determined) of 5-HT were dispensed into all wells of the microplate, and the integrated area was recorded for 20 s as described above for agonists.
Miniaturized assays. Small-volume, or miniaturized, aequorin assays were conducted in black, sterile, clear-bottom, tissue culture-treated, small-volume, 384-well polystyrene microplates (Greiner Bio-One, Germany) and 1536-well polystyrene microplates (Greiner Bio-One) using CyBi Lumax™ (CyBio USA, Woburn, MA). For miniaturized 384-well assays, serially diluted compounds were plated from polypropylene microplates into assay microplates in 1 of 2 ways: CyBio CyBi-Well 384-well pipettor for aequous intermediate dilution compound transfers or the Echo 550 acoustic dispenser (LabCyte) for nanoliter-range compound dispenses. In the miniaturized 384-well and 1536-well agonist assays, the Lumax dispensed 2 μL of cells into either 2 μL of a 2× aequous serial dilution of agonists or 20 nL of a 100× DMSO serial dilution such that the assay concentration of each initial dilution point was 50 μM. The integrated area was calculated for 20 s immediately following each cell dispensation and recorded using CyBi Lumax software. Miniaturized antagonist assays were conducted similar to the antagonist method for standard-volume assays. Specifically, 2 μL of cells were dispensed on 2 μL of 2× aequous serial dilution of antagonists, followed by a 15-min roomtemperature incubation and a 2-μL addition of a 3× EC 50 concentration (previously determined) of 5-HT before a 20-s read.
Raw data files were collected from the FDSS and Lumax and analyzed using GraphPad Prism™. All EC 50 and IC 50 values were determined using a single-site logistic equation. For agonists, maximal efficacy (E MAX ) was determined as a percentage of the average response observed for saturating concentrations of 5-HT. Antagonism was described as percentage control, where the responses of antagonized cells are compared as a percentage of the average response of control cells observed for an EC 50 concentration of 5-HT.
RESULTS AND DISCUSSION
Effects of cell density on 5-HT 2b pharmacology in aequorin
One of the proposed advantages provided by the use of aequorin was that, unlike fluorescence-based detection, with inherent S:B limitations, the luminescent assay would possess a larger dynamic range, which may be reflected as an overall gain in statistical robustness reflected in signal window (SW), Z, and Z′ calculations while retaining the appropriate pharmacology. 20 To test this hypothesis, the effect of differing cell densities on agonist pharmacology was examined. Figure 1 illustrates the concentration response effects to 5-HT under varying cell conditions. In these experiments, we observed that although the maximum signal increased as a function of cell density, the EC 50 across conditions was consistent with less than 2-fold variation. The increase in signal as a function of cell density is consistent with previous observations made by Le Poul and others 15 for the Orexin 2 receptor. In addition, the background luminescence as judged by the lowest concentration of 5-HT tested did not vary among differing cell densities except for the highest condition tested. Using these data, we evaluated the robustness of the assay at various concentrations of agonist as a function of cell density. Table 1 displays screening statistics for 2 screening scenarios, agonist as well as antagonist identification. In the agonist scenario in which the maximal agonist response (EC 100 ) was compared with no agonist addition, we observed that increasing cell number resulted in an increase in S:B; however, the SW, which is a statistical measurement that incorporates the variability of each of the responses and measures the distances between the high and low controls, increased between 1000 and 2000 cells per well but then decreased with higher densities. However, the observation that both the 2000 cells per well and 4000 cells per well condition yielded greater S:B, SW, and Z′ values compared with the 1000 cells per well condition strongly suggests that increasing cell density can positively affect assay robustness in an agonist screening scenario but that an optimal density does exist. The divergence between S:B and SW is accounted for by increased variability of the response at the EC 100 condition at higher cell densities (see the error bars in Fig. 1) . Note that the Z′ statistic was calculated to be greater than 0.5 in all densities tested, the minimal threshold typically used in HTS. 20 In the antagonist scenario in which the EC 50 response was compared with buffer addition, we observed a similar increase in S:B across cell densities as expected. In addition, we observed that the SW increased as a function of cell density and that the maximal cell density tested yielded the highest SW and largest Z′ value. These results are explained by analysis of the variation at each concentration along the concentration response curve (see Fig. 1 ). Fluorescence assays in which submaximal agonist concentrations typically yield highly variable responses make the antagonist screening scenario assay less robust, which was confirmed in the present set of experiments (see fluorescence values in Table 1 ). In contrast, the aequorin assay yielded less variable responses at lower concentrations relative to saturating and thereby provided a statistically more robust assay when screening for antagonists. (To date, we have made similar observations regarding the differences in variability in the aequorin response at saturating versus submaximal agonist concentrations for multiple agonists across multiple receptors; unpublished observations). These results indicate that 1) the aequorin assay is sufficiently robust for agonist and antagonist identification; 2) in contrast to fluorescence assays, the robustness of the assay can be manipulated by altering cell density without an effect on pharmacology; 3) in the aequorin format, antagonist screening is equally (if not more) robust as agonist screening; and 4) antagonist screening may be amenable to the use of lower agonist concentration to provide sufficient signal for hit identification.
Aequorin enables functional GPCR screening at or below the agonist EC 50
Although successful functional antagonist screening campaigns can be executed with fluorescence-based detection of calcium mobilization, they typically must be run at near saturating (EC 80 ) concentrations of probing agonist to achieve sufficient assay robustness. As a result, these assays can have limited sensitivity to low-potency antagonists as well as potential shifts in potency relative to assays executed at or below the EC 50 and/or K d of probing ligand. Drawing on the finding that varying cell density can affect SW in the aequorin format, we examined the ability to use lower probing agonist concentrations in an antagonist-seeking setting. In this experiment, we expanded the number of wells to sample a greater population of responses in representative highand low-signal samples. Figure 2 shows that indeed, acceptable Z values (>0.5) can be obtained at EC 30 concentrations of probing agonist and in a miniaturized format. In this experiment, varying cell densities were tested under a constant agonist condition. The results presented for the 2500 cells per well condition were found to be optimal with respect to plate-to-plate reproducibility and Z values, demonstrating the population response in the plate was statistically uniform (ref. Z factor).
5-HT 2b pharmacological comparison of FLUO-4 and aequorin: large-volume aequous intermediate dilution
The sensitivity of an assay format is determined not only by the statistical robustness as judged by Z′ values but also by the pharmacology (potency and efficacy) of test compounds. In the next series of experiments, we used known agonists, partial agonists, and antagonists to compare the pharmacology of the 2 assay formats. First, we employed an assay format (typically used by Bristol-Myers Squibb Company [BMS]) in which test compounds are diluted in aequous buffer to a concentration 2 times the final concentration and subsequently transferred to the cell plate for assessment. The agonist potencies and efficacies at the 5-HT 2b receptor observed during the pharmacological comparison of FLUO-4 and aequorin are summarized in Table 2 . Agonist assays were conducted in 40-μL volumes, and antagonist assays were performed in 60-μL volumes. To control for cell density in the large-volume format and the likelihood that a large-volume fluorescence assay would yield insufficient signal at lower cell densities, both assays were conducted at 20,000 cells/well and yielded acceptable Z′ values (data not shown).
In each assay format, the potency for test agonists ranked consistently and is in agreement with previously published reports. 15, 16 However, absolute potency does vary from previous reports depending on the study cited. With respect to efficacy, BW-723C86 exhibited the highest partial efficacy relative to 5-HT, with SCH-23390 exhibiting equivalent and/or less intrinsic activity than 8-OH DPAT (see Fig. 3 ). Within this set of compounds, SCH-23390 has been reported to have the lowest intrinsic activity, and our results are consistent with previous reports. 21, 22 When compared with each other, rank ordering of potency and efficacy is preserved; however, there does appear to be a trend for a 5-to 7-fold rightward shift in potency in the aequorin format versus fluorescence.
Next, we investigated the potency of 4 previously reported antagonists. Although we demonstrated that the aequorin format is amenable to the use of lower probing agonist concentrations, for the purpose of direct comparison, each assay format was run at an EC 80 concentration of 5-HT, with no 5-HT activation serving as 100% inhibition. The data from the antagonist experiments comparing FLUO-4 versus aequorin are summarized in Table 3 . In both assay formats, the antagonist potencies rank ordered as follows: methiothepin = LY-53,857 > mianserin > SB-204741, which is consistent with previously published reports. 15 Unlike the agonist comparison, no trend for a shift in potency was observed between the 2 formats.
Miniaturization of aequorin assay: small-volume 384-and 1536-well assays
We determined the feasibility of miniaturizing both agonist and antagonist aequorin assays into small-volume plates. By using miniaturized assay formats, we enabled the delivery of neat sample to both the agonist and antagonist assays and therefore could examine the impact of compound delivery on pharmacology. Data are shown as the mean ± SEM from 3 independent experiments.
Direct transfer of neat compound in DMSO into assay
The Echo 550™ acoustic dispenser was used to add 20 nL of test compounds dissolved in 100% DMSO directly into the assay, thereby avoiding the aequous dilution step. For agonist assays, a final cell density of 2000 cells/well was used in small-volume 384-well and 1536-well assays. The potencies and efficacies of 5-HT 2b agonists in this assay are reported in Table 4 . In the smallvolume 384-well format, the potency rankings were 5-HT > BW-723C86 > SCH-23390 > 8-OH DPAT. The efficacies ranked as follows: 5-HT > BW-723C86 > SCH-23390 = 8-OH DPAT. In 1536-well format, the potency rankings were 5-HT > BW-723C86 > SCH-23390 > 8-OH DPAT, and the efficacies ranked as follows: 5-HT > BW-723C86 > SCH-23390 = 8-OH DPAT. Concentration response curves for individual compounds are presented in Figure 4 . In comparing these data with the initial aequorin data presented in Table 1 , 5-HT as well as BW-723C86 exhibited a leftward shift in potency, whereas SCH-23390 and 8-OH DPAT were relatively unaffected (i.e., less than 3-fold difference) by delivery of neat sample into the assay, thus minimizing the previously observed difference relative to the fluorescence assay. In addition, we observed that the absolute intrinsic activity as well as rank order was unaffected by sample delivery method.
The potencies of antagonists in the small-volume 384-and 1536-well formats in the acoustic dispense assay are summarized in Table 5 . In these experiments a final cell density of 2500/well was used in the small-volume 384-well and 1536-well experiments. The rank order for SV-384 was LY-53,857 > methiothepin > mianserin > SB-204741. For the 1536-well format, the rank order was LY-53,857 > methiothepin > SB-204741 = mianserin. The corresponding concentration response curves are presented in Figure  4B . Comparison with previous data reported in Table 3 demonstrates that delivery of neat sample for the antagonist assay did not significantly alter potency (i.e., less than 3-fold difference) or rank ordering. A 2L final volume kinetic calcium mobilization assay was enabled for HTS for small molecule modulators of GPCRs.
CONCLUSION
We have investigated aequorin-based detection of calcium mobilization as a means for enabling miniaturized functional GPCR HTS campaigns. One limiting factor of fluorescence-based detection of GPCR signaling is the inherent finite and relatively small S:B that can be generated in this assay format. In our 1st set of experiments, we demonstrated that manipulation of cell density can dramatically increase S:B, SW, and Z′ values without altering agonist pharmacology, thereby leading to a more robust assay. The finding that both the S:B statistic and the statistics that incorporate signal variation such as SW and Z′ are greater supports the hypothesis that the difference in magnitude of the response observed in aequorin significantly contributes to overall robustness (i.e., for the Z′ calculation, the increase of the denominator is greater than the increase in the numerator when comparing aequorin against fluorescence). The ability to manipulate SW and Z′ via changes in cell density offers several advantages over conventional fluorescence assays. First, it may allow for more robust assays for poorly expressed and/or poorly coupled receptor targets that exhibit minimally detectable signals using fluorescence detection. Unlike the fluorescence assay in which an increasing cell number proportionally increases background, the aequorin platform does not present significant alterations in basal luminescence (see Fig. 1) . Second, the ability to manipulate the amount of signal has the potential to enhance the sensitivity of antagonist screens by enabling the achievement of acceptable Z′ values at lower probing agonist concentrations. Indeed, we observed that we could achieve acceptable Z values for a mock antagonist assay using an EC 30 concentration of agonist as compared with an EC 80 concentration typically employed by fluorescence-based assays. Overall, this feature should improve the ability of the functional assay to detect less potent inhibitors and may improve assay connectivity with assays run at or below the K d of the probing ligand. Although the aequorin assay has the advantage of yielding more robust assays as compared with fluorescence, as demonstrated by larger Z′ values. For the assay to be accepted as a viable substitute, it must be able to produce comparable pharmacology to that of the currently employed assay format. To examine this directly, we tested several agonists of varying potencies and efficacies as well as antagonists in the 2 formats to understand potential differences in absolute values as well as rank ordering. In addition, because the pharmacological response to a given compound can be subject to prior handling, we evaluated concentration response values using compounds supplied from aequous dilution as well as neat DMSO sources. Under large-volume (>40 μL) conditions, we observed that each assay format produced the same rank ordering of agonist potency and efficacies consistent with previous reports. 21, 22 However, under these conditions, there tended to be a rightward shift in potency in the aequorin assay as compared with fluorescence. In contrast, the antagonist rank ordering as well as absolute potency values were in agreement between the 2 assay formats. Based on this limited set of agonist data, the conclusion could be made that the aequorin assay may produce a rightward shift in agonist pharmacology. However, there are additional untested variables, including comparison of adherent versus cell suspension and direct examination of receptor expression under these differing cell-handling conditions. In addition, the aequous intermediate process may better accommodate slow-to-dissolve compounds. Finally, this observation may be explained by 1) the difference in calcium affinity for each detection employed and/or 2)
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Transfer ( the subcellular compartment in which the calcium measurement is occurring (i.e., in the cytosol for fluorescence v. the mitochondria for aequorin). When comparing a miniaturized assay format that employed neat sample dispensation directly into the assay, we observed a significant shift toward greater potency of both 5-HT and BW723C86, therefore demonstrating that sample presentation can significantly affect potency of individual compounds. Also of note is that only a subset of compounds was affected by sample delivery, and we did not observe a systematic change in potency values in diluted versus neat DMSO conditions. Overall, the rank order of efficacy and potency was maintained across all experimental conditions. Therefore, when comparing the pharmacology of individual test compounds, it is important to consider not only the detection platform but also the process by which the platform would be implemented. In the case of the antagonists tested, we observed no significant difference among aequorin versus fluorescence and neat sample delivery versus diluted. We conclude that the aequorin assay offers several advantages over the fluorescence-based methods for HTS of GPCR-induced calcium mobilization. Furthermore, we conclude that subtle differences in pharmacology may exist between the 2 assay formats. However, this is based on a limited set of compounds tested in 1 cell line. We also have demonstrated that the aequorin format is highly amenable to miniaturization to the 1536-well format, thereby enabling delivery of neat DMSO sample directly to the assay, thereby minimizing the impact of aequous compatibility, a wellestablished issue regarding compound presentation in screening campaigns. 23 Overall, the ability to miniaturize while maintaining and/or increasing statistical robustness of agonist and antagonist hit identification assays as well as the enablement of neat sample presentation have led to the implementation of the aequorin assay format at BMS.
